Floatz logo

Kur-502

NHL, Relapsed, Adult

Athenex, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

410 Active assets in the NHL, Relapsed, Adult cohort.

View all 50

Same molecule, other indications

Kur-502 is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell adult acute lymphocytic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →